Reference no: EM131462732

Immunologists are working with a mutation (HER2) that is expressed on the surface of many breast, bladder, pancreatic, and ovarian cancer cells. They have made antibodies against this mutant surface protein. These antibodies have been covalently bonded to a "gene expression vector" that makes cells light up when incubated with luciferin from fire flies. The vector takes the gene for luciferin into the cancer cells. The researchers have shown that their antibody can accurately find and "light up" cancer cells. Their next step is to bond the antibody to an expression vector that carries the normal HER2 gene into mutant cancer cells.

Would this discovery be more useful for a) reducing cancer risks, b) correcting/restoring cancer cells to normal, or c) destroying cancerous tissue?